Deferiprone: Clinical Trials

12 trials of Deferiprone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 4 unknown, 1 withdrawn. 12 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 312Completed 7, Unknown 4, Withdrawn 1
Phase 26Unknown 4, Completed 2

Follow Deferiprone: new trials by email Literature Review of Deferiprone trials Research Report on Deferiprone

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis
Deferiprone, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis
Phase 2 / Phase 3CompletedUniversity Hospital, Lille3722019-01-302025-12-05
Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy
Deferiprone, Acetylcysteine, Sitagliptin and Metformin - Diabetes Mellitus, Iron Metabolism Disorders
Phase 2 / Phase 3UnknownHadassah Medical Organization202016-12-012016-08-29
An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients
Deferiprone - Beta Thalassemia Major
Phase 2 / Phase 3UnknownAin Shams University642014-07-012015-01-14
Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration
Deferiprone oral solution - Pantothenate Kinase-Associated Neurodegeneration
Phase 3CompletedApoPharma682014-06-012020-08-25
Role of Vitamin C to Augment Iron Chelation With DFP or DFX
Vitamin C, Defriprone, deferisarox, deferiprone , deferesarox - Vitamin c, Thalassemia Major
Phase 2 / Phase 3UnknownAin Shams University502014-04-012014-03-11
Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
Deferiprone, Deferasirox - Chronic Iron Overload
Phase 3CompletedConsorzio per Valutazioni Biologiche e Farmacologiche4352014-03-172021-05-04
Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)
Deferiprone oral solution, Placebo - Pantothenate Kinase-Associated Neurodegeneration
Phase 3CompletedApoPharma892012-12-132019-07-05
Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
DFP (ferriprox) and deferasirox (ICL 670), DFP, DFO - Beta-thalassemia Major, Sickle Cell Disease
Phase 2 / Phase 3UnknownAin Shams University602012-02-012012-02-06
Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
deferiprone, Placebo - Acute Kidney Injury
Phase 3WithdrawnCorMedix Therapeutics2012-01-012020-08-24
Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease
deferiprone, placebo - Parkinson's Disease
Phase 2 / Phase 3CompletedUniversity Hospital, Lille402009-10-012026-05-14
Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients
Deferiprone - Iron Overload
Phase 3CompletedApoPharma1002007-08-012009-09-02
Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients
Deferiprone (L1), Desferrioxamine - Hemochromatosis
Phase 3CompletedLipomed952002-01-012012-11-19

Conditions studied

beta-Thalassemia (4)  ·  Iron Overload (2)  ·  Pantothenate Kinase-Associated Neurodegeneration (2)  ·  Acute Kidney Injury (1)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Anemia, Sickle Cell (1)  ·  Diabetes Mellitus (1)  ·  Hearing Loss, Sensorineural (1)  ·  Hemochromatosis (1)  ·  Iron Metabolism Disorders (1)  ·  Optic Atrophy (1)  ·  Parkinson Disease (1)  ·  Peptic Ulcer (1)  ·  Thalassemia (1)

Sponsors

Ain Shams University (3)  ·  ApoPharma (3)  ·  University Hospital, Lille (2)  ·  Consorzio per Valutazioni Biologiche e Farmacologiche (1)  ·  CorMedix Therapeutics (1)  ·  Hadassah Medical Organization (1)  ·  Lipomed (1)

Countries

Egypt (6)  ·  Italy (3)  ·  United Kingdom (3)  ·  France (2)  ·  Germany (2)  ·  United States (2)  ·  Albania (1)  ·  Cyprus (1)  ·  Greece (1)  ·  Indonesia (1)  ·  Israel (1)  ·  Malaysia (1)  ·  Tunisia (1)  ·  Turkey (Türkiye) (1)

Top investigators

Elliott Vichinsky, MD (2)  ·  Thomas Klopstock, MD (2)  ·  Amal M El-Beshlawy, Prof. Dr. (1)  ·  Aurelio Maggio, MD (1)  ·  David Devos, MD, PhD (1)  ·  David Devos, MD,PhD (1)  ·  David Zangen, Professor (1)  ·  Donato Bonifazi, Dr (1)  ·  Fernando Tricta, MD (1)  ·  Mohsen S Elalfy, professour (1)  ·  Mohsen S. Elalfy, professour (1)  ·  Nardo Nardocci, MD (1)  ·  Patrick Chinnery, MD (1)  ·  Prof. Mohsen S El Alfy, MD (1)

Results publications

PMID 18055982, PMID 18351337, PMID 20921906, PMID 22180427, PMID 24251381, PMID 25600572, PMID 25943368, PMID 29119631, PMID 31202468, PMID 32470438, PMID 33926431, PMID 37975597, PMID 37975798

NIH funding

2008 (1), 2017 (1)